Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies

Bone

Volumn 47, Issue 2, 2010, Pages 169-180

  Giusti, Andrea ^a   Hamdy, Neveen A T ^a   Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atypical femur fractures; Bisphosphonate; Glucocorticoids; Insufficiency fractures; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLUCOCORTICOID; VITAMIN D; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT;

AGED; BONE DENSITY; BONE TURNOVER; CASE STUDY; CLINICAL ASSESSMENT; DRUG EFFICACY; FEMALE; FEMUR FRACTURE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PREVALENCE; REVIEW; RISK FACTOR; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; AGE DISTRIBUTION; BONE REMODELING; CHEMICALLY INDUCED; DEMOGRAPHY; META ANALYSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PUBLICATION; RADIOGRAPHY; STANDARDS; TIME;

ADULT; AGE DISTRIBUTION; AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DEMOGRAPHY; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; HUMANS; MIDDLE AGED; PUBLICATIONS; RISK FACTORS; TIME FACTORS;

EID: 77955981091     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.05.019     Document Type: Review

References (75)

1. Papapoulos S.E. Bisphosphonates for postmenopausal osteoporosis. Primer on the metabolic bone diseases and disorders of mineral metabolism (seventh edition) 2008, 237-241. American Society for Bone and Mineral Research, Washington, DC. C.J. Rosen (Ed.).
2. Russell R.G.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 2008, 19:733-759.
3. Cremers S.C., Pillai G., Papapoulos S.E. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin. Pharmacokinet. 2005, 44:551-570.
4. Watts N.B., Diab D.L. Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab. 2010, 95:1555-1565.
5. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J. Med. 2004, 350:1189-1199.
6. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5years of treatment. The Fracture Intervention Trial long-term extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
7. Mellstrom D.D., Sorensen O.H., Goemaere S., Roux C., Johnson T.D., Chines A.A. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif. Tissue Int. 2004, 75:462-468.
8. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 2005, 90:1294-1301.
9. Goh S.K., Yang K.Y., Koh J.S., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J. Bone Joint Surg. Br. 2007, 89:349-353.
10. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J. Orthop. Trauma 2008, 22:346-350.
11. Kwek E.B., Goh S.K., Koh J.S., Png M.A., Howe T.S. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39:224-231.
12. Nieves J.W., Bilezikian J.P., Lane J.M., et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos. Int. 2010, 21:399-408.
13. Salminen S., Pihlajamäki H., Avikainen V., Kyrö A., Böstman O. Specific features associated with femoral shaft fractures caused by low-energy trauma. J. Trauma 1997, 43:117-122.
14. Weiss R.J., Montgomery S.M., Al Dabbagh Z., Jansson K.A. National data of 6409 Swedish inpatients with femoral shaft fractures: stable incidence between 1998 and 2004. Injury 2009, 40:304-308.
15. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J. Bone Miner. Res. 2009, 24:1095-1102.
16. Martin-Hunyadi C., Heitz D., Kaltenbach G., et al. Spontaneous insufficiency fractures of long bones: a prospective epidemiological survey in nursing home subjects. Arch. Gerontol. Geriatr. 2000, 31:207-214.
17. Kumm D.A., Rack C., Rütt J. Subtrochanteric stress fracture of the femur following total knee arthroplasty. J. Arthroplasty 1997, 12:580-583.
18. Niimi R., Hasegawa M., Sudo A., Uchida A. Unilateral stress fracture of the femoral shaft combined with contralateral insufficiency fracture of the femoral shaft after bilateral total knee arthroplasty. J. Orthop. Sci. 2008, 13:572-575.
19. Chalmers J. Subtrochanteric fractures in osteomalacia. J. Bone Joint Surg. Br. 1970, 52:509-513.
20. Salminen S.T., Pihlajamäki H.K., Avikainen V.J., Böstman O.M. Population based epidemiologic and morphologic study of femoral shaft fractures. Clin. Orthop. Relat. Res. 2000, 372:241-249.
21. Lenart B.A., Neviaser A.S., Lyman S., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos. Int. 2009, 20:1353-1362.
22. Black D.M., Kelly M.P., Genant H.K., Palermo L., Eastell R., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J. Med. 2010, 362:1761-1771.
23. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J. Med. 2008, 358:1304-1306.
24. Schilcher J., Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009, 80:413-415.
25. Spivacow F.R., Sarli M., Buttazzoni M. Treatment with bisphosphonates and atypical fractures. Medicina (B Aires) 2009, 69:612-618.
26. Kelly W.N., Arellano F.M., Barnes J., et al. Guidelines for submitting adverse event reports for publication. Drug Saf. 2007, 30:367-373.
27. Koh J.S., Goh S.K., Png M.A., Kwek E.B., Howe T.S. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?. J. Orthop. Trauma 2010, 24:75-81.
28. Napoli N., Novack D., Armamento-Villareal R. Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies. Osteoporos. Int. 2010, 21:705-708.
29. Grasko J.M., Herrmann R.P., Vasikaran S.D. Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates. J. Oral Maxillofac. Surg. 2009, 67:645-649.
30. Wernecke G., Namdari S., Dicarlo E.F., Schneider R., Lane J. Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid. HSS J 2008, 4:123-127.
31. Cermak K., Shumelinsky F., Alexiou J., Gebhart M.J. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin. Orthop. Relat. Res. 2009, published online December 18. 10.1007/s11999-009-1192-0.
32. Bunning R.D., Rentfro R.J., Jelinek J.S. Low-energy femoral fractures associated with long-term bisphosphonate use in a rehabilitation setting: a case series. PM R 2010, 2:76-80.
33. Armamento-Villareal R., Napoli N., Diemer K., et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif. Tissue Int. 2009, 85:37-44.
34. Armamento-Villareal R., Napoli N., Panwar V., Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J. Med. 2006, 355:2048-2050.
35. Leung F., Lau TW, To .M., Luk KDK, Kung A.W.C. A typical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Rep. 2009, published online March 5. 10.1136/bcr.10.2008.1073.
36. Ing-Lorenzini K., Desmeules J., Plachta O., Suva D., Dayer P., Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009, 32:775-785.
37. Lee P., Seibel M.J. More on atypical fractures of the femoral diaphysis. N Engl J. Med. 2008, 359:317.
38. Levy S., Odvina C., Palnitkar S., Rao D.S. Unusual femoral shaft fractures following long term bisphosphonate therapy. J. Bone Miner. Res. 2004, 19(Suppl 1):S492.
39. Makras P., Hamdy N.A., Zwinderman A.H., Ballieux B.E., Papapoulos S.E. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. Bone 2009, 44:766-771.
40. Somford M.P., Geurts G.F., den Teuling J.W., Thomassen B.J., Draijer W.F. Long-term alendronate use not without consequences?. Int. J. Rheumatol. 2009, 2009:253432. 10.1155/2009/253432.
41. Husada G., Libberecht K., Peeters T., Populaire J. Bilateral mid-diaphyseal femoral stress fractures in the elderly. Eur. J. Trauma 2005, 31:68-71.
42. Schneider J.P. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006, 61:31-33.
43. Lee P., van der Wall H., Seibel M.J. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J. Endocrinol. Invest. 2007, 30:590-597.
44. Cheung R.K., Leung K.K., Lee K.C., Chow T.C. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med. J. 2007, 13:485-489.
45. Demiralp B., Ilgan S., Ozgur Karacalioglu A., Cicek E.I., Yildrim D., Erler K. Bilateral femoral insuffiency fractures treated with inflatable intramedullary nails: a case report. Arch Orthop Trauma Surg 2007, 127:597-601.
46. Visekruna M., Wilson D., McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility. J. Clin. Endocrinol. Metab. 2008, 93:2948-2952.
47. Sayed-Noor A.S., Sjödén G.O. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy-a case report. Acta Orthop. 2008, 79:565-567.
48. Schneider J.P. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 2009, 64:18-23.
49. Ali T., Jay R.H. Spontaneous femoral shaft fracture after long-term alendronate. Age Ageing 2009, 38:625-626.
50. Goddard MS Reid K.R., Johnston JC Khanuja H.S. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 2009, 32. http://www.orthosupersite.com/view.aspx?rid=41933, 10.3928/01477447-20090624-27.
51. Edwards M.H., McCrae F.C., Young-Min S.A. Alendronate-related femoral diaphysis fracture-what should be done to predict and prevent subsequent fracture of the contralateral side?. Osteoporos. Int. 2010, 21:701-703.
52. Capeci C.M., Tejwani N.C. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J. Bone Joint Surg. Am. 2009, 91:2556-2561.
53. Sayed-Noor A.S., Sjödén G.O. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin. Orthop. Relat. Res. 2009, 467:1921-1926.
54. Bush L.A., Chew F.S. Subtrochanteric femoral insufficiency fracture in woman on bisphosphonate therapy for glucocorticoid-induced osteoporosis. Radiol. Case Rep. 2009, 4:261. http://radiology.casereports.net/index.php/rcr/article/view/261/575, 10.2484/rcr.v4i1.261.
55. Lee J.K. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium. Int. J. Rheum. Dis. 2009, 12:149-154.
56. Somford M.P., Draijer F.W., Thomassen B.J., Chavassieux P.M., Boivin G., Papapoulos S.E. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J. Bone Miner. Res. 2009, 24:1736-1740.
57. Glennon D.A. Subtrochanteric stress fractures in six patients on long term bisphosphonate therapy: a case series. Bone 2009, 44(Suppl 1):S77-S78. 10.1016/j.bone.2009.01.172.
58. Odvina C.V., Levy S., Rao S., Zerwekh J.E., Rao D.S. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin. Endocrinol. (Oxf) 2010, 72:161-168.
59. Whyte M.P. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J. Bone Miner. Res. 2009, 24:1132-1134.
60. Daffner R.H., Pavlov H. Stress fractures: current concepts. AJR Am. J. Roentgenol. 1992, 159:245-252.
61. Papapoulos S.E. Bisphosphonates: how do they work?. Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22:831-847.
62. Israel O., Front D., Hardoff R., Ish-Shalom S., Jerushalmi J., Kolodny G.M. In vivo SPECT quantitation of bone metabolism in hyperparathyroidism and thyrotoxicosis. J. Nucl. Med. 1991, 32:1157-1161.
63. 99mTc-methylene diphosphonate with age: relevance to the pathogenesis of bone loss. J. Nucl. Med. 2000, 41:1478-1483.
64. Burr D.B., Diab T., Koivunemi A., Koivunemi M., Allen M.R. Effects of 1 to 3years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J. Orthop. Res. 2009, 27:1288-1292.
65. Bilezikian J., Klemes A., Silverman S., Cosman F. Subtrochanteric fracture reports coincident with risedronate use. J. Bone Miner. Res. 2009, 24(Suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=0367cfaa-4d0d-47d8-a57a-ff76098839a2.
66. Giusti A., Papapoulos S.E. Treatment of male osteoporosis with bisphosphonates. Osteoporosis in men: the effects of gender on skeletal health (second edition) 2009, 667-679. Academic Press (Elsevier), London. B.J.P. Orwoll ES, D. Vanderschueren (Eds.).
67. Fournier M.R., Targownik L.E., Leslie W.D. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas 2009, 64:9-13.
68. Gold D.T., Bonnick S.L., Amonkar M.M., Kamel H.K., Agarwal S., Zaidi M. Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy. Gend. Med. 2008, 5:374-384.
69. Schwartz AV Bauer D.C., Cummings S.R., Cauley JA Ensrud K.E., et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J. Bone Miner. Res. 2010, published online January 8. 10.1002/jbmr.11.
70. Chavassieux P.M., Arlot M.E., Roux J.P., et al. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J. Bone Miner. Res. 2000, 15:754-762.
71. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 1997, 100:1475-1480.
72. Eriksen E.F., Melsen F., Sod E., Barton I., Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002, 31:620-625.
73. Boivin G., Bala Y., Chapurlat R.D., Delmas P.D. Long-term treatment with oral bisphosphonates in postmenopausal women: effects on the degree of mineralization and microhardness of bone. J. Bone Miner. Res. 2008, 23(Suppl 1):S10.
74. Zoehrer R., Roschger P., Paschalis E.P., et al. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J. Bone Miner. Res. 2006, 21:1106-1112.
75. Roschger P., Lombardi A., Misof BM Maier G., et al. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the Fracture Intervention Trial Long-Term Extension (FLEX). J. Bone Miner. Res. 2009, published online December 4. 10.1359/jbmr.060401.